

A randomised, double-blind, placebo-controlled, dose-ranging two-centre study to evaluate the efficacy and safety of Devil's Claw in the treatment of knee and hip osteoarthritis

Submission date 13/11/2006	Recruitment status Stopped	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 13/12/2006	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 05/08/2021	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Sarah Brien

Contact details

Complementary Medicine Research Unit
University of Southampton
Aldermoor Health Centre
Aldermoor Close
Southampton
United Kingdom
SO16 5ST
+44 (0)23 8024 1069
sbb@soton.ac.uk

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00295490

Protocol serial number

Study information

Scientific Title

A randomised, double-blind, placebo-controlled, dose-ranging two-centre study to evaluate the efficacy and safety of Devil's Claw in the treatment of knee and hip osteoarthritis

Study objectives

1. Devil's Claw has anti-inflammatory properties (as assessed by the reduction in pain, stiffness and disability aspects on the Western Ontario and McMaster Universities Arthritis Index [WOMAC]) in chronic osteoarthritis (OA) of the knee and/or hip after 16 weeks of treatment, as compared to placebo.
2. A dose response effect exists in the treatment of osteoarthritis of the knee/hip by Devil's Claw.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Southampton and South West Hampshire, Local Research Ethics Committees, approval: 14/04/2004, ref: LREC 049/04/t

Study design

Randomised double-blind placebo-controlled dose-ranging two-centre study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Osteoarthritis of knee and/or hip

Interventions

Patients randomised to one of four groups:

1. Placebo medication
2. Devil's Claw (240 mg/d extract, equivalent dose of 2.4 - 4.8 mg/d)
3. Devil's Claw (960 mg/d extract, equivalent dose of 9.6 - 19.2 mg/d)
4. Devil's Claw (1920 mg/d extract, equivalent dose of 19.2 - 40.4 mg/d)

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Devil's Claw (*Harpagophytum procumbens*)

Primary outcome(s)

Reduction in WOMAC total score from baseline to week 16.

Key secondary outcome(s)

1. Secondary efficacy analysis
2. Change in WOMAC subscales (pain, stiffness, disability) from baseline to end of treatment at week 16
3. Quality of Life assessments (Short Form health survey [SF-36])
4. Changes in the subject's well-being
5. Changes in subject's overall global assessment
6. Changes in attitudes and health beliefs to Complementary/Alternative Medicine (CAM)
7. Group differences between adverse event reporting

Completion date

30/09/2008

Reason abandoned (if study stopped)

Lack of funding/sponsorship

Eligibility

Key inclusion criteria

1. Patients with either a pragmatic diagnosis of:
 - 1.1. Osteoarthritis of the knee, with no other known rheumatological condition and who report the following clinical features (based on the American College of Rheumatology [ACR] classification for knee OA1):
 - 1.1.1. Knee pain on most days of the previous month
 - 1.1.2. Morning stiffness of less than 30 minutes duration
 - 1.1.3. "Stiffness" in resting the joint, and
 - 1.1.4. Aged over 40 years
 - 1.2. Osteoarthritis of the hip, with no other known rheumatological condition and who report the following clinical features (based on the ACR classification for hip OA2) - hip pain on most days of the previous month and at least two of the following three features:
 - 1.2.1. Erythrocyte sedimentation rate (ESR) less than 20 mm/hour
 - 1.2.2. Radiographic femoral or acetabular osteophytes
 - 1.2.3. Radiographic joint space narrowing (superior, axial and/or medial), and
 - 1.2.4. Aged over 45 years of ageThe diagnosis of osteoarthritis will be confirmed by X-ray.
2. Only patients who have grade 2 to 4 of the Kellgren and Lawrence scale will be recruited (The Kellgren and Lawrence scale ranges from grade zero to grade four where grades zero and one represent doubtful osteoarthritic changes and therefore a doubtful diagnosis)
3. Patients who have been on stable medication (conventional or complementary, including nutritional medicine) for the past three months, but are still getting symptoms (incomplete responders)
4. Only those patients who record baseline pain scores on the WOMAC scale of at least 20 mm on the Visual Analogue Scale (VAS) for a minimum of six out of seven days monitored during the period from Clinic Visit one (screening) and Clinic Visit two (baseline)
5. Ability to comply with the requirements of the study and to give informed consent
6. For women of child-bearing potential: negative pregnancy test

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Participation in an investigational trial within 30 days prior to enrolment
2. Previous treatment with Devil's Claw within 90 days prior to enrolment
3. Patients awaiting a replacement knee or hip joint
4. Patients with other conditions that cause pain
5. Patients with congenital dislocation of the hip
6. Patients who have had operations on their hip due to previous trauma
7. Patients with severe co-morbidities - including severe cardiac or pulmonary disease and cancer
8. Dementia, psychoses, or other significant impairment of mental status that would prohibit sufficient comprehension, provision of informed consent and to allow undertaking of the necessary self-care or toxicity reporting
9. Patients taking corticosteroid medication
10. Known allergies against any of the ingredients of the treatments
11. Patients who would be unable to complete the self assessment forms, or to attend for X-ray and clinical examination
12. Patients with other known rheumatic disease such as rheumatoid arthritis
13. Patients with the diagnosis gout
14. Patients who report a red or hot swollen joint (which is unlikely to be due to OA), and would require further rheumatological assessment
15. Patients with conditions known to be contraindicated to the study medication i.e. patients with gastric or duodenal ulcers; gallstones; patients taking drugs for arrhythmias; patients with heart failure
16. Patients who are pregnant, trying to become pregnant or breastfeeding

Date of first enrolment

12/12/2004

Date of final enrolment

30/09/2008

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre
University of Southampton
Southampton
United Kingdom
SO16 5ST

Sponsor information

Organisation
University of Southampton (UK)

ROR
<https://ror.org/01ryk1543>

Funder(s)

Funder type
Research organisation

Funder Name
Southampton Complementary Medicine Research Trust (UK)

Funder Name
University of Southampton (UK)

Alternative Name(s)
University of Southampton UK

Funding Body Type
Government organisation

Funding Body Subtype
Universities (academic only)

Location
United Kingdom

Funder Name
Pascoe Pharmazeutische Präparate GmbH (Germany)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results		09/09/2011		No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes